Alembic Pharma Shares in Spotlight Following Investment in Canadian Venture

Alembic Pharmaceuticals' Canadian Expansion Plans Spark Interest

Alembic Pharmaceuticals' share price is likely to remain in focus on June 8, following the company's announcement of a shareholders' agreement to invest in a newly incorporated Canadian entity, Canada Inc. The company has partnered with Difgen Holdings LLC and Sukhad Juneja to invest in shares of 17989377 Canada Inc.

The newly formed corporation will serve as a platform for the development, commercialization, distribution, and marketing of pharmaceutical products in Canada. Under the agreement, Alembic Pharmaceuticals and Difgen Holdings LLC will each hold a 45 percent stake in the venture, while the remaining 10 percent equity will be held by other investors.

Pharmaceutical Expansion in Canada

Read also: Three Indian IPOs Scheduled for Listing on Dalal Street This Week.

Alembic Pharmaceuticals has also made significant strides in the US market, receiving final approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Haloperidol Tablets USP on June 5. The approved product is therapeutically equivalent to Haldol Tablets of Ortho McNeil Pharmaceutical. Haloperidol tablets are used in the management of psychotic disorders and for the control of tics and vocal utterances associated with Tourette’s Disorder in both children and adults.

Financial Performance

On the financial front, Alembic Pharmaceuticals reported a 29.2 percent year-on-year increase in consolidated net profit at Rs 202.7 crore for the quarter ended March 2026, compared with Rs 156.9 crore in the corresponding quarter last year. Revenue from operations rose 4.4 percent to Rs 1,847.7 crore from Rs 1,769.6 crore a year ago.

Read also: Momentum Stocks Decline: TCS, RVNL, eClerx Services, and SBI Cards Reach 52-Week Lows

Alembic Pharmaceuticals shares ended at Rs 736.95, up 0.17 percent in the previous trading session. The stock has declined around 33 percent from its 52-week high of Rs 1,107.80 touched on June 30, 2025, while remaining about 16 percent above its 52-week low of Rs 635.30 hit on March 23, 2026. The company commands a market capitalisation of Rs 14,485.7 crore.